Detalhe da pesquisa
1.
Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial.
Haematologica
; 109(2): 543-552, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37560813
2.
New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta-2 microglobulin in patients with diffuse large B-cell lymphoma treated with R-CHOP: Spanish Lymphoma Group Experience (GELTAMO).
Br J Haematol
; 188(6): 888-897, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31782146
3.
RELINF: prospective epidemiological registry of lymphoid neoplasms in Spain. A project from the GELTAMO group.
Ann Hematol
; 99(4): 799-808, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-32076827
4.
Evaluation of the MD Anderson tumor score for diffuse large B-cell lymphoma in the rituximab era.
Eur J Haematol
; 104(5): 400-408, 2020 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-31804029
5.
The Cardiovascular Event Risk Associated with Tyrosine Kinase Inhibitors and the Lipid Profile in Patients with Chronic Myeloid Leukemia.
Hematol Rep
; 16(1): 140-150, 2024 Mar 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38534885
6.
Treatment outcomes in patients with large B-cell lymphoma after progression to chimeric antigen receptor T-cell therapy.
Hemasphere
; 8(5): e62, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38774657
7.
Impact of SCHOLAR-1 Criteria on Chimeric Antigen Receptor T Cell Therapy Efficacy in Aggressive B Lymphoma: A Real-World GELTAMO/GETH Study.
Transplant Cell Ther
; 29(12): 747.e1-747.e10, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37659694
8.
Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups.
Front Immunol
; 13: 855730, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35911769
9.
New therapies for relapsed or refractory aggressive B-cell lymphoma increase survival: Analysis from the RELINF registry of the GELTAMO group.
Hemasphere
; 8(4): e70, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38650598
10.
Spontaneous remission after a year of romiplostim in an adult patient with refractory primary immune thrombocytopenia.
Ann Hematol
; 91(9): 1497-8, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22373551
11.
Positive Impact of Eculizumab Therapy on Surgery for Budd-Chiari Syndrome in a Patient with Paroxysmal Nocturnal Hemoglobinuria and a Long-Term History of Thrombosis.
Hematol Rep
; 8(3): 6562, 2016 Sep 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-27757214